Form 4: Kestra Medical Officer Sells 10,500 Shares

Kestra Medical Technologies' General Counsel and Chief Administrative Officer, Traci S. Umberger, sold 10,500 common shares for a weighted average price of $26.6858 per share under a pre-arranged 10b5-1 trading plan.

Summary

• Traci S. Umberger, a Director and Officer (General Counsel and Chief Administrative Officer) of Kestra Medical Technologies, Ltd. (KMTS), reported a sale of common shares.
• The transaction involved the disposition of 10,500 common shares.
• The shares were sold at a weighted average price of $26.6858 per share, with prices ranging from $26.51 to $26.96.
• This sale was executed on December 29, 2025, under a Rule 10b5-1 trading plan adopted on September 30, 2025.
• Following this transaction, Umberger directly beneficially owns 136,633 common shares.
• The reported beneficial ownership includes 12,797 common shares received from West Affum Holdings, L.P. in a pro rata distribution exempt under Rule 16a-9.

Sentiment

Score: 5

Explanation: The transaction is a pre-planned insider sale, which is generally neutral in sentiment. It does not indicate a change in company fundamentals or a lack of confidence, as it was scheduled in advance.

Industry Context

This insider transaction is a routine disclosure for a publicly traded medical technology company. It reflects an individual's pre-planned stock sale rather than a broader industry trend or strategic move by Kestra Medical Technologies.

Related Party Transactions

• The beneficial ownership includes 12,797 Common Shares received from West Affum Holdings, L.P. in a pro rata distribution exempt pursuant to Rule 16a-9, which could be considered a related party transaction if West Affum Holdings, L.P. is a related entity.

Stakeholder Impact

• Shareholders may observe a slight increase in the public float of shares, but the impact is minimal given the pre-planned nature of the sale and the relatively small percentage of total shares outstanding.

Key Dates

Recommendation

The reported transaction is a routine insider sale executed under a Rule 10b5-1 trading plan, which indicates a pre-scheduled disposition not necessarily tied to new material non-public information. This type of transaction typically has a neutral impact on the company's fundamentals and does not warrant a change in investment recommendation based solely on this filing. Investors should continue to hold and monitor broader company performance and market conditions.

Keywords

Kestra Medical Technologies, KMTS, Insider Trading, Form 4, Stock Sale, Traci S. Umberger, 10b5-1 Plan, Officer Transaction, Director Transaction, Equity Disposition